Takeda Lowers Profit Outlook Amid Vyvanse Loss of Exclusivity, Eyes $900M Restructuring in 2024 5/9/2024

Women's Health: Where Politics and Science Meet 5/9/2024

Attovia Secures $105M Series B to Expand I&I Pipeline of Bispecific Antibodies 5/9/2024

Lisata’s Autologous T Cell Therapy Is Safe but Fails to Slow T1D Disease Progression, Trial Finds 5/9/2024

Bespoke Gene Therapy Consortium Targets AAVs for Rare Diseases 5/9/2024

Keytruda Strikes Out Again in Endometrial Cancer with Phase III Flop 5/9/2024

DEIB Evolves As Criticism, Changing Attitudes Continue 5/9/2024

Dry Promotions: Dealing With a Double-Edged Sword 5/9/2024

Top 5 Companies Hiring in the Boston Area 5/9/2024

Pfizer Eyes Broader Label for RSV Vaccine Abrysvo After Promising Phase III Data 4/9/2024

Nvelop and Seaport Raise $100M in Rounds, Tap Bluebird and Karuna Execs 4/9/2024

FDA Backs BrainStorm’s Design for Phase IIIb Trial in Early-Stage ALS 4/9/2024

EMA to Review Diabetes and Weight-Loss Drugs for Suicidal Ideation Risk 4/9/2024

AbbVie’s Humira Loses Only 4% of Market Share to Biosimilars: Report 4/9/2024

Lilly Pays $3.2B to Buy Morphic and Deepen Immunology, Gastro Portfolio 7/8/2024

Grifols Gets $6B Takeover Offer from Founding Family, Brookfield to Go Private 7/8/2024

Myricx Bio Raises $115M in Series A to Advance ADC With Lilly and Novo Backing 7/8/2024

GLP-1s May Cut Risk of 10 Obesity-Related Cancers in Diabetes Patients: Study 7/8/2024

Roche Axes Phase II/III NSCLC Study as TIGIT Drug Loses to Keytruda-Chemo Combo 7/8/2024

Boehringer Ingelheim Loses Legal Challenge to IRA in Federal Court Ruling 7/8/2024